A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma

Br J Haematol. 2018 Aug;182(3):429-433. doi: 10.1111/bjh.14793. Epub 2017 Jun 23.

Authors

Guy Pratt¹, Christina Yap², Ceri Oldreive³, Daniel Slade², Rebecca Bishop², Mike Griffiths⁴, Martin J S Dyer⁵, Chris Fegan⁶, David Oscier⁷, Andrew Pettitt⁸, Estella Matutes⁹, Stephen Devereux¹⁰, David Allsup¹¹, Adrian Bloor¹², Peter Hillmen¹³, George Follows¹⁴, Simon Rule¹⁵, Paul Moss¹⁶, Tatjana Stankovic³

Affiliations

¹ University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
² Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.
³ Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
⁴ West Midlands Regional Genetics Laboratory, Birmingham, UK.
⁵ Department of Cancer Studies, University of Leicester, Leicester, UK.
⁶ Cardiff and Vale University Health board, University Hospital of Wales, Cardiff, UK.
⁷ Royal Bournemouth and Christchurch NHS Foundation Trust, Bournemouth, UK.
⁸ The Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK.
⁹ Royal Marsden NHS Foundation Trust, London, UK.
¹⁰ King's College Hospital NHS Foundation Trust, London, UK.
¹¹ Hull York Medical School, Hull, UK.
¹² The Christie NHS Foundation Trust, Manchester, UK.
¹³ St James University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
¹⁴ Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
¹⁵ Plymouth Hospitals NHS Trust, Plymouth, UK.
¹⁶ University of Birmingham, Birmingham, UK.

PMID: 28643365
DOI: 10.1111/bjh.14793

No abstract available

Keywords: DNA damage; chronic lymphocytic leukaemia; mantle cell lymphoma; olaparib.

Publication types

Clinical Trial, Phase I
Letter
Multicenter Study
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Ataxia Telangiectasia Mutated Proteins / genetics
DNA Damage / genetics
Female
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell / mortality
Leukemia, Prolymphocytic, T-Cell / drug therapy
Leukemia, Prolymphocytic, T-Cell / mortality
Lymphoma, Mantle-Cell / drug therapy
Lymphoma, Mantle-Cell / mortality
Lymphoproliferative Disorders / drug therapy*
Lymphoproliferative Disorders / mortality
Male
Maximum Tolerated Dose
Middle Aged
Phthalazines / administration & dosage
Phthalazines / adverse effects
Phthalazines / therapeutic use*
Piperazines / administration & dosage
Piperazines / adverse effects
Piperazines / therapeutic use*
Poly(ADP-ribose) Polymerase Inhibitors / adverse effects
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use
Recurrence
Survival Analysis
Tumor Suppressor Protein p53 / genetics

Substances

Phthalazines
Piperazines
Poly(ADP-ribose) Polymerase Inhibitors
TP53 protein, human
Tumor Suppressor Protein p53
ATM protein, human
Ataxia Telangiectasia Mutated Proteins
olaparib

Associated data

ISRCTN/ISRCTN34386131

Grants and funding